[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Trials Update
June 26, 2018

MDMA-Assisted Psychotherapy for PTSD

JAMA. 2018;319(24):2470. doi:10.1001/jama.2018.8168

The psychoactive agent MDMA (3,4-methylenedioxymethamphetamine) delivered in an outpatient psychiatric clinic with intensive psychotherapy is safe and may enhance the benefits of psychotherapy in the treatment of posttraumatic stress disorder (PTSD), concluded a phase 2 study published in Lancet Psychiatry.

Twenty-six military veterans and first responders with chronic PTSD were randomly assigned to psychotherapy plus 1 of 3 MDMA dose groups: 30 mg (active control), 75 mg, or 125 mg. Participants received 3 initial 90-minute psychotherapy sessions to prepare for the MDMA experience. The agent was administered in two 8-hour sessions of specially adapted psychotherapy sessions about 1 month apart. Each session was followed by an overnight stay onsite, 7 days of telephone contact, and three 90-minute psychotherapy sessions.